
Irene Cano-Pumarega

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7920049/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Moderate obstructive sleep apnea and cardiovascular outcomes in older adults: a propensity score–matched multicenter study (CPAGE-MODE study). Journal of Clinical Sleep Medicine, 2022, 18, 553-561.	2.6	2
2	[Translated article] International consensus document on obstructive sleep apnea. Archivos De Bronconeumologia, 2022, 58, T52-T68.	0.8	10
3	Untreated obstructive sleep apnea and cardiovascular outcomes in patients with acute symptomatic pulmonary embolism. Thrombosis Research, 2022, 214, 87-92.	1.7	4
4	Special considerations for treatment of sleep-related movement disorders. , 2021, , .		0
5	Sleep-Related Rhythmic Movement Disorder. Sleep Medicine Clinics, 2021, 16, 315-321.	2.6	9
6	Restless Legs Syndrome - Clinical Features. Sleep Medicine Clinics, 2021, 16, 233-247.	2.6	4
7	Correlation between systemic iron parameters and substantia nigra iron stores in restless legs syndrome. Sleep Medicine, 2021, 85, 191-195.	1.6	6
8	Upcoming Scenarios for the Comprehensive Management of Obstructive Sleep Apnea: An Overview of the Spanish Sleep Network. Archivos De Bronconeumologia, 2020, 56, 35-41.	0.8	9
9	Quantitative transcranial sonography of the substantia nigra as a predictor of therapeutic response to intravenous iron therapy in restless legs syndrome. Sleep Medicine, 2020, 66, 123-129.	1.6	21
10	Obesity attenuates the effect of sleep apnea on active TGF-ß1 levels and tumor aggressiveness in patients with melanoma. Scientific Reports, 2020, 10, 15528.	3.3	8
11	Proangiogenic factor midkine is increased in melanoma patients with sleep apnea and induces tumor cell proliferation. FASEB Journal, 2020, 34, 16179-16190.	0.5	11
12	Iron Replacement Therapy in Restless Legs Syndrome. Current Treatment Options in Neurology, 2020, 22, 1.	1.8	6
13	Low risk of iron overload or anaphylaxis during treatment of restless legs syndrome with intravenous iron: a consecutive case series in a regular clinical setting. Sleep Medicine, 2020, 74, 48-55.	1.6	5
14	Emerging Concepts of the Pathophysiology and Adverse Outcomes of Restless Legs Syndrome. Chest, 2020, 158, 1218-1229.	0.8	17
15	Obstructive Sleep Apnea: Emerging Treatments Targeting the Genioglossus Muscle. Journal of Clinical Medicine, 2019, 8, 1754.	2.4	34
16	Non-dopaminergic vs. dopaminergic treatment options in restless legs syndrome. Advances in Pharmacology, 2019, 84, 187-205.	2.0	17
17	Reduced response to gabapentin enacarbil in restless legs syndrome following long-term dopaminergic treatment. Sleep Medicine, 2019, 55, 74-80.	1.6	25
18	Continuous Positive Airway Pressure Treatment Does not Reduce Uric Acid Levels in OSA Women. Archivos De Bronconeumologia, 2019, 55, 201-207.	0.8	2

IRENE CANO-PUMAREGA

#	Article	IF	CITATIONS
19	Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients. European Respiratory Journal, 2019, 53, 1801298.	6.7	27
20	Treating restless legs syndrome in the context of sleep disordered breathing comorbidity. European Respiratory Review, 2019, 28, 190061.	7.1	15
21	Treatment of restless legs syndrome/Willis-Ekbom disease with the non-selective ENT1/ENT2 inhibitor dipyridamole: testing the adenosine hypothesis. Sleep Medicine, 2018, 45, 94-97.	1.6	44
22	Management of treatment failure in restless legs syndrome (Willis-Ekbom disease). Sleep Medicine Reviews, 2018, 41, 50-60.	8.5	25
23	Biomarkers of carcinogenesis and tumour growth in patients with cutaneous melanoma and obstructive sleep apnoea. European Respiratory Journal, 2018, 51, 1701885.	6.7	27
24	Sleep-Disordered Breathing Is Independently Associated With Increased Aggressiveness of Cutaneous Melanoma. Chest, 2018, 154, 1348-1358.	0.8	58
25	Intermittent Hypoxia Is Associated With High Hypoxia Inducible Factor-1α but Not High Vascular Endothelial Growth Factor Cell Expression in Tumors of Cutaneous Melanoma Patients. Frontiers in Neurology, 2018, 9, 272.	2.4	16
26	New concepts in the management of restless legs syndrome. BMJ: British Medical Journal, 2017, 356, j104.	2.3	61
27	Multi-center, randomized, placebo-controlled trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease: a study protocol for the INOX trial. BMC Pulmonary Medicine, 2017, 17, 8.	2.0	30
28	Treatment of restless legs syndrome with the selective AMPA receptor antagonist perampanel. Sleep Medicine, 2017, 34, 105-108.	1.6	44
29	Sleep Apnea and Hypertension. Chest, 2017, 152, 742-750.	0.8	51
30	A prospective multicenter cohort study of cutaneous melanoma: clinical staging and potential associations with HIF-11 \pm and VEGF expressions. Melanoma Research, 2017, 27, 558-564.	1.2	23
31	Effect of continuous positive airway pressure on blood pressure and metabolic profile in women with sleep apnoea. European Respiratory Journal, 2017, 50, 1700257.	6.7	30
32	Impact of obstructive sleep apnea on cardiovascular outcomes in patients with acute symptomatic pulmonary embolism: Rationale and methodology for the POPE study. Clinical Cardiology, 2017, 40, 1182-1188.	1.8	13
33	Sex differences in the association between obstructive sleep apnea and hypertension—what's next?. Journal of Thoracic Disease, 2017, 9, E1156-E1157.	1.4	1
34	Continuous Positive Airway Pressure Improves Quality of Life in Women with Obstructive Sleep Apnea. A Randomized Controlled Trial. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1286-1294.	5.6	71
35	Obstructive Sleep Apnea and Systemic Hypertension. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1299-1304.	5.6	151
36	Recurrent tuberculosis from 1992 to 2004 in a metropolitan area. European Respiratory Journal, 2007, 30, 333-337.	6.7	32